title: Mesenchymal stem cell-based angiotensin-converting enzyme 2 in treatment of acute lung injury rat induced by bleomycin.
abstract: BACKGROUND
  Acute lung injury (ALI) is a high incidence disease with no effective therapeutic method (mortality rate > 40%). The aim of this study was to find a new and effective therapeutic method for ALI.
  
  
  METHODS
  After the isolation of human umbilical cord mesenchymal stem cells (HUMSCs) from cesarean fetus, we transfected the HUMSCs with Lenti-ACE2 (angiotensin-converting enzyme 2) viral particles. Then we evaluated the therapeutic effect of HUMSCs harboring ACE2 on ALI, which induced by bleomycin (BLM) in rat model.
  
  
  RESULTS
  Our results showed that HUMSCs harboring ACE2 could attenuate ALI degree through reducing pulmonary inflammatory infiltration and degree of vascular permeability, repressing the mRNA level of pro-inflammatory cytokines, activating the mRNA level of anti-inflammatory cytokines and ACE2. Besides, results also demonstrated that HUMSCs harboring ACE2 gene had higher therapeutic effects to ALI than the single factor of HUMSCs or ACE2.
  
  
  CONCLUSIONS
  This research provided clues for the development of effective therapeutic methods to ALI using stem cell transplantation and gene therapy.
authors.affiliation: 1Department of Respiratory Medicine, Shanghai JianGong Hospital, Shanghai, P. R. China.
authors.forename: Fengying
authors.initials: F
authors.lastname: Gao
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Lili
authors.initials: L
authors.lastname: Hou
authors.forename: Zhuozhe
authors.initials: Z
authors.lastname: Li
authors.forename: Fang
authors.initials: F
authors.lastname: Min
authors.forename: Zhenwei
authors.initials: Z
authors.lastname: Liu
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000628:therapy*; D000085962:Angiotensin-Converting Enzyme 2; D000818:Animals; D001761:Bleomycin; D015153:Blotting, Western; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D007703:Peptidyl-Dipeptidase A / Q000235:genetics* / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D010641:Phenotype; D011897:Random Allocation; D051381:Rats; D016019:Survival Analysis; D014183:Transplantation, Heterologous; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D015847:Interleukin-4; D007371:Interferon-gamma; D009195:Peroxidase; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; C000705329:Ace2 protein, rat; D000085962:Angiotensin-Converting Enzyme 2
keywords: effective therapeutic method; pulmonary inflammatory infiltration; respiratory